82 FR 44429 - National Institute on Aging; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 183 (September 22, 2017)

Page Range		44429-44429
FR Document		2017-20230

Federal Register, Volume 82 Issue 183 (Friday, September 22, 2017)

[Federal Register Volume 82, Number 183 (Friday, September 22, 2017)]
[Notices]
[Page 44429]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-20230]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Aging; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel; Drug Repurposing for Alzheimer's Disease.
    Date: October 17, 2017.
    Time: 10:30 a.m. to 12:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute on Aging, Gateway Building, Suite 
2W200, 7201 Wisconsin Avenue, Bethesda, MD 20814 (Telephone 
Conference Call).
    Contact Person: Anita H. Undale, Ph.D., MD, Scientific Review 
Branch, National Institute on Aging, Gateway Building, Suite 2W200, 
7201 Wisconsin Avenue, Bethesda, MD 20892, 240-747-7825, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging 
Research, National Institutes of Health, HHS)

    Dated: September 18, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-20230 Filed 9-21-17; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 183 / Friday, September 22, 2017 / Notices 44429

information and copies of the U.S. opportunities, please contact Chris DEPARTMENT OF HEALTH AND
patent applications listed below may be Kornak, 240–627–3705, chris.kornak@ HUMAN SERVICES
obtained by communicating with the nih.gov.
indicated licensing contact at the National Institutes of Health
Dated: September 12, 2017.
Technology Transfer and Intellectual
Property Office (TTIPO), 5601 Fishers Suzanne Frisbie, National Eye Institute; Notice of Closed
Lane, Suite 6D, MSC 9804, Rockville, Deputy Director, Technology Transfer and Meeting
MD 20892, tel: 301–496–2644, fax: 240– Intellectual Property Office, National Institute
Pursuant to section 10(d) of the
627–3117. A signed Confidential of Allergy and Infectious Diseases.
Federal Advisory Committee Act, as
Disclosure Agreement will be required [FR Doc. 2017–20232 Filed 9–21–17; 8:45 am]
amended, notice is hereby given of the
to receive copies of unpublished patent BILLING CODE 4140–01–P following meeting.
applications. The meeting will be closed to the
SUPPLEMENTARY INFORMATION: public in accordance with the
Technology descriptions follow. DEPARTMENT OF HEALTH AND provisions set forth in sections
HUMAN SERVICES 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Research Material: A Potent, Broadly-
as amended. The grant applications and
Neutralizing, Anti-HIV Antibody National Institutes of Health the discussions could disclose
(35O22) That Binds a Novel Epitope
confidential trade secrets or commercial
Description of Technology: Millions of National Institute on Aging; Notice of property such as patentable material,
people are infected with HIV–1 Closed Meeting and personal information concerning
worldwide. In the U.S., there are about individuals associated with the grant
30,000 new cases of HIV infection Pursuant to section 10(d) of the
applications, the disclosure of which
reported annually. Researchers at NIAID Federal Advisory Committee Act, as would constitute a clearly unwarranted
are actively investigating broadly amended, notice is hereby given of the invasion of personal privacy.
neutralizing anti-HIV–1 antibodies following meeting.
Name of Committee: National Eye Institute
which can be used as therapeutics or The meeting will be closed to the Special Emphasis Panel NEI; Institutional
prophylactics for HIV infection. public in accordance with the Training Grant Applications.
NIAID and Scripps researchers have provisions set forth in sections Date: October 16, 2017.
discovered a potent anti-HIV antibody 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Time: 8:00 a.m. to 5:00 p.m.
(35O22) that binds a novel HIV epitope. Agenda: To review and evaluate grant
as amended. The grant applications and applications.
This antibody neutralizes at least 80% the discussions could disclose Place: Hilton Garden Inn Bethesda, 7301
of HIV isolates tested so far. The unique confidential trade secrets or commercial Waverly Street, Bethesda, MD 20814.
binding of 35O22 makes it an attractive property such as patentable material, Contact Person: Jeanette M. Hosseini,
candidate to combine with other HIV Ph.D., Scientific Review Officer, NEI/DEA/
and personal information concerning
antibodies or antivirals in treating or SRB, National Institutes of Health, 5635
individuals associated with the grant
preventing HIV infection. Fishers Lane, Suite 1300, Bethesda, MD
This technology is available for applications, the disclosure of which 20892, 301–451–2020, jeanetteh@
licensing for commercial development would constitute a clearly unwarranted mail.nih.gov.
in accordance with 35 U.S.C. 209 and 37 invasion of personal privacy. (Catalogue of Federal Domestic Assistance
CFR part 404, as well as for further Name of Committee: National Institute on Program Nos. 93.867, Vision Research,
development and evaluation under a Aging Special Emphasis Panel; Drug National Institutes of Health, HHS)
research collaboration. Repurposing for Alzheimer’s Disease. Dated: September 18, 2017.
Potential Commercial Applications: Date: October 17, 2017. Natasha M. Copeland,
• HIV–1 therapeutics Time: 10:30 a.m. to 12:00 p.m. Program Analyst, Office of Federal Advisory
• HIV–1 prophylactics Agenda: To review and evaluate grant Committee Policy.
Competitive Advantages: applications.
[FR Doc. 2017–20178 Filed 9–21–17; 8:45 am]
Place: National Institute on Aging,
• Unique epitope BILLING CODE 4140–01–P
Gateway Building, Suite 2W200, 7201
• Broad neutralization of HIV isolates
Wisconsin Avenue, Bethesda, MD 20814
Development Stage: Pre-Clinical. (Telephone Conference Call).
Inventors: Mark Connors, John DEPARTMENT OF HEALTH AND
Contact Person: Anita H. Undale, Ph.D.,
Mascola, Peter Kwong, Tongqing Zhou, HUMAN SERVICES
MD, Scientific Review Branch, National
Jinghe Huang, Byong Ha Kang, all of Institute on Aging, Gateway Building, Suite
NIAID, NIH; Andrew Ward, Scripps National Institutes of Health
2W200, 7201 Wisconsin Avenue, Bethesda,
Research Institute. MD 20892, 240–747–7825, anita.undale@ National Cancer Institute; Notice of
Publications: Huang, J et al., Broad nih.gov. Closed Meetings
and potent HIV–1 neutralization by a
(Catalogue of Federal Domestic Assistance
human antibody that binds the gp41– Pursuant to section 10(d) of the
Program Nos. 93.866, Aging Research,
gp120 interface. Nature 515, 138–142. Federal Advisory Committee Act, as
National Institutes of Health, HHS)
Intellectual Property: Not applicable. amended, notice is hereby given of the
Licensing Contact: Chris Kornak, 240– Dated: September 18, 2017. following meetings.
627–3705, chris.kornak@nih.gov. Melanie J. Pantoja, The meetings will be closed to the
Collaborative Research Opportunity: Program Analyst, Office of Federal Advisory public in accordance with the
The Technology Transfer and Committee Policy. provisions set forth in sections
Intellectual Property Office (TTIPO) is [FR Doc. 2017–20230 Filed 9–21–17; 8:45 am]
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
seeking parties interested in as amended. The grant applications and
BILLING CODE 4140–01–P
collaborative research to further develop the discussions could disclose
35O22 in combination with other NIAID confidential trade secrets or commercial
antibodies. For collaboration property such as patentable material,

VerDate Sep<11>2014 18:11 Sep 21, 2017 Jkt 241001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 E:\FR\FM\22SEN1.SGM 22SEN1

Document Created: 2017-09-22 01:52:48
Document Modified: 2017-09-22 01:52:48

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		October 17, 2017.
FR Citation		82 FR 44429

82 FR 44429 - National Institute on Aging; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 183 (September 22, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health